Swedish prospective multicenter trial evaluating sentinel lymph node biopsy after neoadjuvant systemic therapy in clinically node-positive breast cancer.
Linda Holmstrand ZetterlundJan FrisellAthanasios ZouzosRimma AxelssonThomas HatschekJana de BonifaceFuat CelebiogluPublished in: Breast cancer research and treatment (2017)
In biopsy-proven node-positive breast cancer, SLNB after NAST is feasible even though the identification rate is lower than in clinically node-negative patients. Since the overall FNR is unacceptably high, the omission of ALND should only be considered if two or more SLNs are identified.
Keyphrases
- positive breast cancer
- lymph node
- sentinel lymph node
- end stage renal disease
- neoadjuvant chemotherapy
- newly diagnosed
- ejection fraction
- ultrasound guided
- chronic kidney disease
- early stage
- clinical trial
- fine needle aspiration
- rectal cancer
- prognostic factors
- randomized controlled trial
- squamous cell carcinoma
- cross sectional
- patient reported outcomes
- radiation therapy
- bone marrow
- replacement therapy